New Huntington's drug enters early human testing
NCT ID NCT07339514
First seen Jan 17, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-phase study tests an experimental drug called ER2001 in 27 adults with early-stage Huntington's disease. The main goal is to check safety and how the drug moves through the body. Participants receive either the drug or a placebo as an IV once a week for 6 weeks, with follow-up for 6 months. This is not a cure, but a step toward finding a treatment that may control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510080, China
-
First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.